NCT00134134View on ClinicalTrials.gov

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

August 31, 2006

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

efalizumab

Trial Locations (1)

10016

New York University School of Medicine, Dept of Dermatology, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

NYU Langone Health

OTHER